NAACCR



ICD-O UpdateEffective January 1, 2021Table 7: Combined 2021 ICD-O-3.2 update (alpha)Status abbreviations used in the update tableStatus DefinitionBCBehavior code change (change in reportability)CCPer ICD-O-3.2, several ICD-O codes have been deleted and the histologies moved to other codes. NC/TNew ICD-O code and termPTPreferred termRTRelated termSynSynonymHistology terms are per WHO. Preferred terms are indicated in BOLD font.Applicable C codes will be noted next to the term in BOLD font.Coding instructions, if applicable, are noted in the “Comments” column.StatusICD-O-3.2MorphologyCodeTerm(s)ReportableY/NCommentsRT8140/3Acinar adenocarcinoma of prostate (C61.9)YSyn8744/3Acral lentiginous melanoma, malignant (C44. _)YPT8744/3Acral melanoma (C44. _)YBC8158/3ACTH-producing tumorYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021PT9840/3Acute erythroid leukemiaYCC9687/3Acute leukemia, Burkitt type [obs]YCases diagnosed prior to 1/1/2021 use code 9826/3Cases diagnosed 1/1/2021 forward use code 9687/3CC9687/3Acute lymphoblastic leukemia, mature B-cell typeYCases diagnosed prior to 1/1/2021 use code 9826/3Cases diagnosed 1/1/2021 forward use code 9687/3NC/T9912/3Acute myeloid leukemia with BCR-ABL1YReportable for cases diagnosed 1/1/2021 forwardNC/T9878/3Acute myeloid leukemia with biallelic mutations of CEBPAYReportable for cases diagnosed 1/1/2021 forwardNC/T9877/3Acute myeloid leukemia with mutated NPM1YReportable for cases diagnosed 1/1/2021 forwardNC/T9879/3Acute myeloid leukemia with mutated RUNX1YReportable for cases diagnosed 1/1/2021 forwardSyn9840/3Acute myeloid leukemia, M6 typeYSyn8140/3Adenocarcinoma, usual typeYPT8390/3Adnexal adenocarcinoma (C44. _)YSyn8700/3Adrenal medullary paraganglioma (C74.1)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn/BC8408/3Aggressive digital papillary adenoma (C44. _) see comments*See commentsThe term “Aggressive digital papillary adenoma” has changed behavior from /1 to /3. Cases diagnosed prior to 1/1/2021 with this term are not reportable. Cases with this term diagnosed 1/1/2021 and after are reportableSyn9310/3Ameloblastoma, malignantYPT9310/3Ameloblastoma, metastasizingYNC/T9715/3Anaplastic large cell lymphoma, ALK negativeYReportable for cases diagnosed 1/1/2021 forwardRT8020/3Anaplastic undifferentiated carcinoma (C73.9)YSyn8691/3Aortic body paraganglioma (C75.5)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021BCSynSyn8691/3Aortic body tumor (C75.5)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn8691/3Aorticopulmonary paraganglioma (C75.5)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn8249/3Atypical carcinoid tumorYCC9687/3B-ALL [obs]YCases diagnosed prior to 1/1/2021 use code 9826/3Cases diagnosed 1/1/2021 forward use code 9687/3RT8090/3Basal cell carcinoma with adnexal differentiation (C44. _) NNot reportableSyn8833/1Bednar tumor (C44. _)NCases diagnosed prior to 1/1/2021, report the case and code to 8833/3. Cases diagnosed 1/1/2021 forward are not reportable.Syn8151/3Beta cell adenoma (C25.4)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021.Syn8151/3Beta cell tumor, malignant (C25.4)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021.NC/T9819/3B-lymphocytic leukemia/lymphoma, BCR-ABL1-likeYReportable for cases diagnosed 1/1/2021 forwardRT9715/3Breast implant-associated anaplastic large cell lymphoma (C50. _)YReportable for cases diagnosed 1/1/2021 forwardSyn9699/3Bronchus associated lymphoid tissue lymphomaYCC9687/3Burkitt cell leukemia (see also M-9687/3)YCases diagnosed prior to 1/1/2021 use code 9826/3Cases diagnosed 1/1/2021 forward use code 9687/3CC9811/3c-ALLYCases diagnosed prior to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3RT8140/3Carcinoma of Skene, Cowper and Littre GlandsYSyn8589/3Carcinoma showing thymus-like elementYRT8020/3 Carcinoma, poorly differentiated, NOSYBC8692/3Carotid body paraganglioma (C75.4)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn8692/3Carotid body tumor (C75.4)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021RT8693/3ChemodectomaYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn8700/3Chromaffin paragangliomaYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn8700/3Chromaffin tumorYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn8700/3ChromaffinomaYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021RT8313/1Clear cell adenofibroma of borderline malignancy (C56.9)NNot reportablePT8313/1Clear cell borderline tumor (C56.9)NNot reportableSyn8313/1Clear cell cystic tumor of borderline malignancy (C56.9)NNot reportableSyn8313/1Clear cell tumor, atypical proliferation (C56.9)NNot reportablePT9473/3CNS Embryonal tumor, NOS YCC9811/3Common ALLYCases diagnosed prior to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3CC9811/3Common precursor B ALLYCases diagnosed prior to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3RT8693/3Composite paragangliomaYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021RT8700/3Composite pheochromocytoma (C74.1)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021RT/BC8500/2Cystic hypersecretory carcinoma (C50. _) YCases diagnosed prior to 1/1/2021, code to 8508/3. ICD-O-3.2 now lists this term under 8500 with a behavior code of 2.RT8020/3Dedifferentiated carcinomaYBC8832/1Dermatofibrosarcoma protuberans, NOSNCases diagnosed prior to 1/1/2021, report the case and code to 8832/3. Cases diagnosed 1/1/2021 forward are not reportable.Syn8832/1Dermatofibrosarcoma, NOSNCases diagnosed prior to 1/1/2021, report the case and code to 8832/3. Cases diagnosed 1/1/2021 forward are not reportable.Syn8832/3Dermatofibrosarcoma, sarcomatous (C44. _)YRT9680/3Diffuse large B-cell lymphoma, activated B-cell subtypeYRT9680/3Diffuse large B-cell lymphoma, germinal center B-cell subtypeYPT9680/3Diffuse large B-cell lymphoma, NOSYPT8408/3Digital papillary adenocarcinoma (C44. _)YRT8720/3Early/Evolving invasive melanoma (C44. _)Y“Early/evolving invasive melanoma” is reportable for cases diagnosed 1/1/2021 forwardRT8720/2Early/Evolving melanoma in situ (C44. _)YEarly/Evolving melanoma in situ is reportable for cases diagnosed 1/1/2021 forwardSyn8408/3Eccrine papillary adenocarcinoma (C44. _)YSyn8409/3Eccrine poroma, malignant (C44. _)YPT8921/3Ectomesenchymoma YSyn8273/3EmbryomaYReportable for cases diagnosed 1/1/2021 forwardRT8509/3Endocrine mucin-producing sweat gland carcinoma (C44. _) YRT8509/2Endocrine mucin-producing sweat gland carcinoma in situ (C44. _) YRT8158/3Endocrine tumor, functioning, NOSYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021RT8140/3Endolymphatic sac tumorYBC8380/2Endometrioid intraepithelial neoplasia (C54.1)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021NC/T9749/3Erdhiem-Chester Disease YReportable for cases diagnosed 1/1/2021 forwardPT9364/3Ewing sarcomaY1/1/2021 forward Ewing sarcoma is the preferred term for 9364/3 and is no longer coded to 9260/3. Cases diagnosed prior to 1/1/2021 should be coded to 9260/3. BC8693/3Extra-adrenal paraganglioma, NOS YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021CC9687/3FAB L3 [obs]YCases diagnosed prior to 1/1/2021 use code 9826/3Cases diagnosed 1/1/2021 forward use code 9687/3Syn8330/3Follicular adenocarcinoma (C73.9)YBC8335/1Follicular carcinoma, encapsulatedNCases diagnosed prior to 1/1/2021 are reportable and coded to 8335/3. Cases diagnosed 1/1/2021 and after are not reportable. PT8330/3Follicular carcinoma, NOS (C73.9)YRT9695/3Follicular lymphoma, duodenal type (C17.0)YRT9690/3Follicular lymphoma, pediatric typeYPT8335/1Follicular tumor of uncertain malignant potentialNSyn8936/3GANTYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021RT8936/3Gastrointestinal autonomic nerve tumorYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021RT8936/3Gastrointestinal pacemaker cell tumorYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn8936/3Gastrointestinal stromal sarcomaYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021BC8936/3Gastrointestinal stromal tumorYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn9411/3Gemistrocytic astrocytoma IDH mutant (C71. _)YSyn8936/3GIST, malignantYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn8690/3Glomus jugulare tumor, NOS (C75.5)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn8315/3Glycogen-rich clear cell carcinomaYBC8620/3Granulosa cell tumor, adult type (C56.9)YGranulosa cell tumor, adult type of the ovary diagnosed prior to 1/1/2021 are not reportable. Cases diagnosed 1/1/2021 forward are now reportable. Syn8815/3Hemangiopericytoma, malignantYCases diagnosed prior to 1/1/2021 use code 9150/3Cases diagnosed 1/1/2021 forward use code 8815/3PT9738/3HHV8-positive diffuse B-cell lymphomaYPT8402/3Hidradenocarcinoma (C44. _)YSyn8077/2High grade squamous intraepithelial lesionYBC9725/1Hydroa vacciniforme-like lymphoproliferative disorderNCases diagnosed prior to 1/1/2021, report the case and code to 9725/3. Cases diagnosed 1/1/2021 forward are not reportableBC9080/1Immature teratoma of the lung (C34. _)NImmature teratomas arising in lung are not reportable for cases diagnosed 1/1/2021 forward.BC9080/1Immature teratoma of the thymus (C37.9)NImmature teratomas arising in thymus are not reportable for cases diagnosed 1/1/2021 forward.BC9080/1Immature teratoma of the thyroid (C73.9)NImmature teratomas arising in thyroid are not reportable for cases diagnosed 1/1/2021 forward.Syn9685/1In situ follicular lymphomaNIn situ lymphoma is not reportableNC9695/1In situ follicular neoplasmNIn situ lymphoma is not reportableSyn9673/1In situ mantle cell lymphomaNNot reportableNC/T9673/1In situ mantle cell neoplasmNNot reportableSyn8337/3Insular carcinoma (C73.9)YBC8151/3Insulinoma, NOS (C25.4) YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021.RT8580/3Intrapulmonary thymoma (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termPT8589/3Intrathyroid thymic carcinoma (C73.9)YRT8150/3Islet cell adenocarcinoma (C25.4)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021RT8150/3Islet cell adenoma (C25.4)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021RT8150/3Islet cell adenomatosis (C25.4)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021RT8150/3Islet cell carcinoma (C25.4)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021RT8150/3Islet cell tumor, NOS (C25.4)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn8690/3Jugular paraganglioma (C75.5)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn8690/3Jugulotympanic paraganglioma (C75.5)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021RT8071/3KeratoacanthomaYBC9751/1Langerhans cell histiocytosis, NOSLangerhans cell histiocytosis, monostoticLangerhans cell histiocytosis, polystoticNNNPlease note, these terms are not reportable. Refer to Hematopoietic Database for reportable terms. Cases diagnosed prior to 1/1/2021, report the case and code to 9751/3. Cases diagnosed 1/1/2021 forward are not reportableSyn9738/3Large B-cell lymphoma arising in HHV8-associated multicentric Castleman diseaseYRT9698/3Large B-cell lymphoma with IRF4 rearrangementYRT8693/3Laryngeal paragangliomaYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021PT8743/3Low cumulative sun damaged melanoma (C44. _)YBC9718/1Lymphoid papulosis (C44. _)NCases diagnosed prior to 1/1/2021, report the case and code to 9718/3. Cases diagnosed 1/1/2021 forward are not reportableBC9766/3Lymphomatoid granulomatosis, grade 3YReportable for cases diagnosed 1/1/2021 forwardSyn9680/3Malignant lymphoma, large B-cell, diffuse, NOSYCC9823/3Malignant lymphoma, lymphocytic, diffuse, NOSYCases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3CC9823/3Malignant lymphoma, lymphocytic, NOSYCases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3CC9823/3Malignant lymphoma, lymphocytic, well differentiated, diffuseYCases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3CC9823/3Malignant lymphoma, small B lymphocytic, NOS (see also M-9823/3)YCases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3CC9823/3Malignant lymphoma, small cell diffuseYCases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3CC9823/3Malignant lymphoma, small cell, NOSYCases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3CC9823/3Malignant lymphoma, small lymphocytic, diffuseYCases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3CC9823/3Malignant lymphoma, small lymphocytic, NOSYCases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3PT8761/3Malignant melanoma arising in giant congenital nevus (C44. _)YSyn8761/3Malignant melanoma in giant pigmented nevus (C44. _)YSyn8982/3Malignant myoepitheliomaYSyn8963/3Malignant rhabdoid tumorYPT8770/3Malignant Spitz tumor (C44. _)YRT8510/3Medullary-like carcinomaYRT9477/3Medulloblastoma, group 3 (C71.6)YRT9477/3Medulloblastoma, group 4 (C71.6)YRT9475/3Medulloblastoma, WNT-activated, anaplastic type (C71.6)YRT9475/3Medulloblastoma, WNT-activated, classic (C71.6)YRT9475/3Medulloblastoma, WNT-activated, large cell type (C71.6)YSyn8780/3Melanoma arising in a blue nevus (C44. _)YRT8720/3Melanoma, meningeal (C70. _)YRT8580/3Metaplastic thymoma (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termPT8407/3Microcystic adnexal carcinoma (C44. _)YBC8690/3Middle ear paraganglioma (C75.5)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn8244/3Mixed carcinoid and adenocarcinomaYRT8770/3Mixed epithelioid and spindle cell melanomaYSyn8482/3Mucinous adenocarcinoma, endocervical typeYRT8470/2Mucinous cystadenocarcinoma, non-invasive (C25. _)YBC8470/2Mucinous cystic neoplasm with high grade dysplasia (C25. _)YSyn9699/3Mucosa associated lymphoid tissue lymphomaYSyn8091/3Multifocal superficial basal cell carcinoma (C44. _)NNot reportableBC9505/0Multinodular and vascolating neuronal tumor (MVNT) (C71.2)YWHO has not yet assigned a specific ICD-O code for this neoplasm. In the interest of collecting these tumors, 9505/0 has been assigned by neuropathology experts.Syn9732/3Multiple myeloma (C42.1)YSyn9986/3Myelodysplastic syndrome with 5q deletion (5q-) syndromeYPT9986/3Myelodysplastic syndrome with isolated del (5q)YPT9985/3Myelodysplastic syndrome with multilineage dysplasiaYPT9993/3Myelodysplastic syndrome with ring sider0blasts and multilineage dysplasia YPT9982/3Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasiaYPT9980/3Myelodysplastic syndrome with single lineage dysplasiaYNC/T9968/3Myeloid/lymphoid neoplasm with PCM1-JAK2YReportable for cases diagnosed 1/1/2021 forwardPT8982/3Myoepithelial carcinomaYRT8150/3Nesidioblastoma (C25.4)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021PT8249/3Neuroendocrine tumor, grade 2YYYRT8249/3Neuroendocrine tumor, grade 3YRemoved from ICD-O-3.29540/1Neurofibromatosis, NOSNWHO has removed neurofibromatosis from ICD-O-3.2. This disease is not reportable for cases diagnosed 1/1/2018 forward per Solid Tumor RulesRT8720/3Nevoid melanoma (C44. _)YSyn8402/3Nodular hidradenoma, malignant (C44. _)YRT8693/3Nonchromaffin paraganglioma, NOS YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021NC/T8349/1Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) C73.9)NThis term was previously coded to 8343/2 and was reportable. This term has changed both ICD-O and behavior codes and is no longer reportable for cases diagnosed 1/1/2021 forward. NC/T8349/1Non-invasive FTPNThis term was previously coded to 8343/2 and was reportable. This term has changed both ICD-O and behavior codes and is no longer reportable for cases diagnosed 1/1/2021 forwardSyn8150/3Pancreatic endocrine tumor, nonfunctioning (C25.4)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021Syn8150/3Pancreatic endocrine tumor, NOS (C25.4)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021BC8150/3Pancreatic neuroendocrine tumor, nonfunctioning (C25.4)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021.PT8342/3Papillary carcinoma, oncocytic variant (C73.9)YSyn8342/3Papillary carcinoma, oxyphilic cell (C73.9)YCC8470/3Papillary mucinous cystadenocarcinoma (C56.9)YCases diagnosed prior to 1/1/2021 use code 8471/3Cases diagnosed 1/1/2021 forward use code 8470/3CC8470/3Papillary pseudomucinous cystadenocarcinoma (C56.9)YCases diagnosed prior to 1/1/2021 use code 8471/3Cases diagnosed 1/1/2021 forward use code 8470/3Syn8441/3Papillary serous adenocarcinoma (C56.9)YCases diagnosed prior to 1/1/2021 use code 8460/3Syn8441/3Papillary serous cystadenocarcinoma (56.9)YCases diagnosed prior to 1/1/2021 use code 8460/3Syn8130/1Papillary transitional cell neoplasm of low-malignant potential (C67. _)NNot reportablePT8130/1Papillary urothelial neoplasm of low-malignant potential (C67. _)NNot reportableRT8083/3Papillary-basaloid carcinomaYBC8681/3Paraganglioma, NOS (C75.5)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021BC8682/3Parasympathetic paraganglioma (C75.5)Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021RT8140/3Parathyroid tumor (C75.0)YSyn8700/3Pheochromoblastoma (C74.1)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021BC8700/3Pheochromocytoma, NOS (C74.1)YReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021BCSyn8833/1Pigmented dermatofibrosarcoma protuberans (C44. _)NCases diagnosed prior to 1/1/2021, report the case and code to 8833/3. Cases diagnosed 1/1/2021 forward are not reportable.PTSyn8110/3Pilomatrical carcinoma (C44. _)Pilomatrix carcinoma (C44. _)NNNot reportableNot reportableNC/T8273/3Pituitary blastoma (C75.1)YReportable for cases diagnosed 1/1/2021 forwardPT9732/3Plasma cell myeloma (C42.1)YSyn8802/3Pleomorphic cell sarcoma, undifferentiatedYRT8802/3Pleomorphic dermal sarcoma (C44. _)YSyn8802/3Pleomorphic sarcomaYBC9971/3Polymorphic post-transplant lymphoproliferative disorderNCases diagnosed prior to 1/1/2021, report the case and code to 9971/3. Cases diagnosed 1/1/2021 forward are not reportableSyn8246/3Poorly differentiated neuroendocrine neoplasmYPT8337/3Poorly differentiated thyroid carcinoma (C73.9)YPT8409/3Porocarcinoma (C44. _)YBC9971/1Post-transplant lymphoproliferative disorder, NOSNCases diagnosed prior to 1/1/2021, report the case and code to 9971/3. Cases diagnosed 1/1/2021 forward are not reportableCC9811/3Pre-B ALLYCases diagnosed prior to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3CC9811/3Precursor B-cell lymphoblastic leukemia (see also M-9728/3)YCases diagnosed prior to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3CC9811/3Precursor B-cell lymphoblastic lymphoma (see also M-9836/3)YCases diagnosed prior to 1/1/2021 use code 9728/3Cases diagnosed 1/1/2021 forward use code 9811/3CC9837/3Precursor T-cell lymphoblastic lymphoma (see also M-9837/3)YCases diagnosed prior to 1/1/2021 use code 9729/3Cases diagnosed 1/1/2021 forward use code 9837/3CC9811/3Pre-pre-B ALLYCases diagnosed prior to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3RT9699/3Primary choroidal lymphoma (C69.3)YBC9718/1Primary cutaneous CD30+ T cell lymphoproliferative disorder (C44. _)NCases diagnosed prior to 1/1/2021, report the case and code to 9718/3. Cases diagnosed 1/1/2021 forward are not reportableBC9709/1Primary cutaneous CD4-positive small/medium T-cell lymphoma (C44. _)NCases diagnosed prior to 1/1/2021, report the case and code to 9709/3. Cases diagnosed 1/1/2021 forward are not reportableCC9811/3Pro-B ALLYCases diagnosed prior to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3RT8074/3Pseudovascular squamous cell carcinomaYBC9971/3PTLD, NOSNCases diagnosed prior to 1/1/2021, report the case and code to 9971/3. Cases diagnosed 1/1/2021 forward are not reportableSyn9980/3Refractory anemiaSyn9982/3Refractory anemia with excess blasts, NOSYRT9985/3Refractory cytopenia of childhoodYSyn9985/3Refractory cytopenia with multilineage dysplasiaYCC9980/3Refractory neutropeniaYCases diagnosed prior to 1/1/2021 use code 9991/3Cases diagnosed 1/1/2021 forward use code 9980/3CC9980/3Refractory thrombocytopenia YCases diagnosed prior to 1/1/2021 use code 9992/3 Cases diagnosed 1/1/2021 forward use code 9980/3PT8963/3Rhabdoid tumor, NOSYSyn8921/3Rhabdomyosarcoma with ganglionic differentiationYSyn8912/3Rhabdomyosarcoma, spindle-cell/sclerosing typeYSyn8407/3Sclerosing sweat duct carcinoma (C44. _)YRT8580/3Sclerosing thymoma (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termSyn8410/3Sebaceous adenocarcinoma (C44. _)YPT8410/3Sebaceous carcinoma (C44. _)YPT9391/3Sellar ependymoma (C75.1)YPT8441/3Serous cystadenocarcinoma, NOS (56.9)YCases diagnosed prior to 1/1/2021 use code 8460/3Syn8441/3Serous papillary adenocarcinoma, NOS (C56.9)YCases diagnosed prior to 1/1/2021 use code 8460/3Syn8441/3Serous surface papillary carcinoma (C56.9)YCases diagnosed prior to 1/1/2021 use code 8460/3Syn8390/3Skin appendage carcinoma (C44. _) YSyn8230/3Solid adenocarcinoma, NOSYRT8452/3Solid pseudopapillary carcinomaYPT8452/3Solid pseudopapillary neoplasm of the pancreas (C25. _)YRT 8120/3Squamotransitional carcinomaYSyn8077/2Squamous dysplasia, high gradeYSyn8077/2Squamous intraepithelial neoplasm, grade IISee commentsThe term “squamous intraepithelial neoplasm, grade II” is NOT reportable for C53. _PT8091/3Superficial basal cell carcinoma (C44. _)NNot reportableRT8743/3Superficial spreading melanoma (C44. _)YRT8200/3Thymic carcinoma with adenoid cystic carcinoma-like features (C37.9)YRT8585/3Thymoma, atypical (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termRT8585/3Thymoma, epithelial (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termRT8583/3Thymoma, lymphocyte-rich (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termRT8583/3Thymoma, lymphocytic (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termRT8581/3Thymoma, medullary (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termRT8582/3Thymoma, mixed type (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termPT8580/3Thymoma, NOS (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termRT8583/3Thymoma, organoid (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termRT8583/3Thymoma, predominantly cortical (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termRT8581/3Thymoma, spindle cell (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termPT8581/3Thymoma, type A (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termPT8582/3Thymoma, type AB (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termPT8583/3Thymoma, type B1 (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termPTRT8584/3Thymoma, type B2 (C37.9)Thymoma, cortical (C37.9)YY“Malignant” removed from pre-ICD-O-3.2 termPT8585/3Thymoma, type B3 (C37.9)Y“Malignant” removed from pre-ICD-O-3.2 termSyn8131/3Transitional cell carcinoma, micropapillaryYSyn8122/3Transitional cell carcinoma, spindle cellPT8122/3Urothelial carcinoma, sarcomatoidYSyn8122/3Urothelial carcinoma, spindle cellYRT8693/3Vagal paragangliomaYReportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021RT9680/3Vitreoretinal lymphoma (C69. _)YRT8054/3Warty-basaloid carcinoma Y ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download